EGFR and neoplasm: Moreover, genetic and histological analysis of tumor biopsies from NSCLC patients with drug resistant tumors showed that all tumors maintained their original activating EGFR mutations and a fraction of them showed a pronounced epithelial-to-mesenchymal transition [23].